New drug combo targets Hard-to-Treat cancers with genetic weakness

NCT ID NCT07277413

Recruiting now Disease control Sponsor: IDEAYA Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 5 times

Summary

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with cancers like lung, stomach, bladder, pancreatic, and mesothelioma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IDE892 (a PRMT5 inhibitor) and IDE397 (a MAT2A inhibitor)
What this could lead to: If successful, this could point toward a new treatment option for several hard-to-treat cancers that have a specific genetic deletion (MTAP).
What could go wrong: This is an early Phase 1 trial, so safety and dosing are still being figured out. It may not work for all cancer types, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus bile duct carcinoma biliary tract cancer esophageal adenocarcinoma esophageal squamous cell carcinoma gastric adenocarcinoma gastroesophageal cancer lung adenocarcinoma malignant pancreatic neoplasm mesothelioma Mesothelioma, Malignant Neoplasm Metastasis non-small cell lung carcinoma pancreatic adenocarcinoma pancreatic neoplasm peritoneal mesothelioma pleural mesothelioma Recurrence transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA OF ESOPHAGUS BILIARY TRACT CARCINOMA BLADDER CANCER GASTRIC ADENOCARCINOMA GASTROESOPHAGEAL CANCER (GC) MESOTHELIOMA NON-SMALL CELL LUNG CANCER (NSCLC) NSCLC ADENOCARCINOMA PANCREATIC CANCER PERITONEAL MESOTHELIOMA PLEURAL MESOTHELIOMA SQUAMOUS CELL CAR. - ESOPHAGUS UROTHELIAL CARCINOMA (UC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

BRCR Global-Coral Springs
RECRUITING

Coral Springs, Florida, 33065, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Johns Hopkins Sibley Memorial Hospital
RECRUITING

Washington D.C., District of Columbia, 20016, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
MD Anderson
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
NEXT Oncology Dallas
RECRUITING

Irving, Texas, 75039, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
NEXT Oncology Houston
RECRUITING

Houston, Texas, 77054, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
NEXT Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Nebraska Cancer Specialists
RECRUITING

Omaha, Nebraska, 68130, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Providence Medical Foundation
RECRUITING

Santa Rosa, California, 95403, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
START Astera, LLC
RECRUITING

East Brunswick, New Jersey, 08816, United States

Contact Email: •••••@•••••
START Dallas Fort Worth
RECRUITING

Fort Worth, Texas, 76104, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
START Mountain Region, LLC
RECRUITING

West Valley City, Utah, 84119, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sarah Cannon Research Institute at Florida Cancer Specialists
RECRUITING

Orlando, Florida, 32827, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

Contact Email: •••••@•••••

Contact Phone: •••-•••-••••
Swedish Cancer Institute
RECRUITING

Seattle, Washington, 98104, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.